- Immunology biotech DiCE Molecules Holdings has set a share price range of between $15 and $17 per share for its IPO.
- At the midpoint, that means the company could raise $160M in the 10M share IPO.
- The company plans to change its name to DICE Therapeutics and trade on the Nasdaq under the ticker "DICE." (DICE)
- BofA Securities, SVB Leerink, and Evercore ISI are the joint bookrunners.
- DICE has a valuation of ~$550M.
- DICE has a proprietary technology platform, DELSCAPE, to develop small molecules for chronic diseases especially in the immunology space.
- Its lead candidate, S011806, is in the IND-enabling phase and targets psoriasis and other IL-17 mediated chronic immunology conditions.
- Seeking Alpha contributor Avisol Capitol Partners gives DICE a neutral rating, noting that all the company's candidates are in the preclinical stage.